Severe morbidity and mortality risk from malaria in the United States, 1985-2011

Open Forum Infectious Diseases

Volumn 1, Issue 1, 2014, Pages

  Hwang, Jimee ^a,b   Cullen, Karen A ^a   Kachur, S Patrick ^a   Arguin, Paul M ^a   Baird, J Kevin ^c,d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Morbidity; Mortality; Plasmodium; Species; USA

Indexed keywords

ARTICLE; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; HUMAN; INFORMATION PROCESSING; MALARIA; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

EID: 84959905024     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu034     Document Type: Article

References (34)

1. Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 2013; 26:36-57.
2. Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77(6 Suppl):79-87.
3. Gething PW, Elyazar IR, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012; 6:e1814.
4. Genton B, D'Acremont V, Rare L, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 2008; 5:e127.
5. McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012; 12:388-96.
6. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 2009; 48:1704-12.
7. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 2008; 46:1374-81.
8. Cullen KA, Arguin PM; Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC). Malaria surveillance-United States, 2011. MMWR Surveill Summ 2013; 62:1-17.
9. Guerra CA, Howes RE, Patil AP, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 2010; 4:e774.
10. Hay SI, Okiro EA, Gething PW, et al. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 2010; 7:e1000290.
11. World Health Organization. World Malaria Report 2013. Geneva: World Health Organization, 2013.
12. Baird JK. Elimination therapy for the endemic malarias. Curr Infect Dis Rep 2012; 14:227-37.
13. Wellems TE, Miller LH. Two worlds of malaria. N Engl J Med 2003; 349:1496-98.
14. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009; 22:13-36.
15. Singh B, Daneshvar C. Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 2013; 26:165-84.
16. Ennis J, Teal AE, Habura A, et al. Simian Malaria in a U.S. Traveler- New York, 2008. Morb Mortal Wkly Rep 2009; 58:229-32.
17. Mali S, Steele S, Slutsker L, et al. Malaria surveillance-United States, 2008. MMWR Surveill Summ 2010; 59:1-15.
18. Mali S, Kachur SP, Arguin PM; Division of Parasitic Diseases and Malaria, Center for Global Health; Centers for Disease Control and Prevention (CDC). Malaria surveillance-United States, 2010. MMWR Surveill Summ 2012; 61:1-17.
19. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009; 22:430-5.
20. Andrade BB, Reis-Filho A, Souza-Neto SM, et al. Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J 2010; 9:13.
21. Barcus MJ, Basri H, Picarima H, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 2007; 77:984-91.
22. Kochar DK, Saxena V, Singh N, et al. Plasmodium vivax malaria. Emerg Infect Dis 2005; 11:132-4.
23. Kochar DK, Tanwar GS, Khatri PC, et al. Clinical features of children hospitalized with malaria-a study from Bikaner, northwest India. Am J Trop Med Hyg 2010; 83:981-9.
24. Manning L, Laman M, Law I, et al. Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One 2011; 6:e29203.
25. Nurleila S, Syafruddin D, Elyazar IR, Baird JK. Serious and fatal illness associated with falciparum and vivax malaria among patients admitted to hospital at West Sumba in eastern Indonesia. Am J Trop Med Hyg 2012; 87:41-9.
26. Shaikh S, Memon H, Iohano B, et al. Severe disease in children hospitalized with a diagnosis of Plasmodium vivax in south-eastern Pakistan. Malar J 2012; 11:144.
27. Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5:e128.
28. Hwang J, McClintock S, Kachur SP, et al. Comparison of national malaria surveillance system with the national notifiable diseases surveillance system in the United States. J Public Health Manag Pract 2009; 15:345-51.
29. Centers for Disease Control and Prevention. In: Brunette G (ed), CDC Health Information for International Travel 2014 (The Yellow Book). New York: Oxford University Press, 2014.
30. Steinhardt LC, Magill AJ, Arguin PM. Review: Malaria chemoprophylaxis for travelers to Latin America. Am J Trop Med Hyg 2011; 85:1015-24.
31. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization, 2010.
32. Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402-15.
33. Schwartz E, Parise M, Kozarsky P, et al. Delayed onset of malaria-implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349:1510-6.
34. Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. Clin Infect Dis 1999; 29:1502-6.